Bayer rival before mega IPO?:
Syngenta is planning a $5 billion IPO in Hong Kong to position itself as a leading supplier in the agricultural sector.
deraktionaer.de/artikel/pharma-biotech/bayer-rivale-vor-mega-ipo-20408799.html
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
Similar to This
Previous
yicaiglobal.com 19h
Bayer to Feature Nearly 30 Innovative Product Debuts at Its Ninth CIIE
yicaiglobal.com/news/ciie-bayer-to-feature-nearly-30-innovative-product-debuts-at-its-ninth-ciie
Bayer stock continues to accelerate: This is what the analysts are now advising: The pharmaceutical business is driving growth.
deraktionaer.de/artikel/pharma-biotech/bayer-aktie-gibt-weiter-gas-das-raten-jetzt-die-analysten-20434432.html
Stock market news this evening: Dax and Dow fall on election day, oil prices rise after US attacks
manager-magazin.de/finanzen/boerse/dax-vor-den-midterm-wahlen-schwaecher-a-2357928a-aaa4-4d3f-abb5-164a89aec8e6
DAX Forecast: Lower - | US Midterms, Bayer, Lufthansa, FMC, BioNTech, AMD, Apple, Palantir in Focus
deraktionaer.de/artikel/indizes/dax-prognose-tiefer-us-midterms-bayer-lufthansa-fmc-biontech-amd-apple-palantir-im-fokus-20431435.html
Bayer delivers strong figures - | but a Monsanto legacy issue could prove costly: Bayer's quarterly results exceed expectations. However, CEO Bill Anderson ...
businessinsider.de/wirtschaft/bayer-liefert-starke-zahlen-doch-eine-monsanto-altlast-koennte-teuer-werden/
Paid articlePaywall
OpinionSyngenta sprinkles too much fertiliser on IPO: The seeds giant is targeting a market value of at least $66 bln, implying its enterprise including debt has ...
reuters.com/commentary/breakingviews/syngenta-sprinkles-too-much-fertiliser-ipo-2026-11-02/
Bayer wins Roundup cancer trial after Supreme Court ruling: The weedkiller Roundup has been accused of being carcinogenic to humans despite no warning on its ...
dw.com/en/bayer-wins-roundup-cancer-trial-after-supreme-court-ruling/a-79803301
Court victory: Bayer's chances for glyphosate settlement increase: US judges in Missouri have once again ruled in favor of Bayer in a glyphosate trial ...
manager-magazin.de/unternehmen/pharma/bayer-gewinnt-ersten-glyphosat-prozess-a-cfdc1fd9-d137-45b1-83d4-bc42e853be30
Bayer stock: Price jump to the top of the DAX - | what the analysts are saying now
deraktionaer.de/artikel/pharma-biotech/bayer-aktie-kurssprung-an-die-dax-spitze-das-sagen-jetzt-die-analysten-20429517.html
Seed Innovation: How Bayer and Syngenta are preparing for climate change: Drought and heat threaten harvests worldwide. How Bayer and Syngenta are countering ...
focusplus.de/finanzen/saatgut-innovation-wie-bayer-syngenta-gegen-klimawandel-ruesten-19201
Paid articlePaywallOpinionSyngenta IPO aims for valuation of at least $66 billion, sources say: Syngenta's advisers are targeting a valuation of at least $66 billion in the Swiss-Chinese ...
reuters.com/legal/transactional/syngenta-aims-valuation-least-66-billion-with-ipo-sources-say-2026-10-27/
Bayer stock falls and falls: Upward trend in danger: Bayer stock falls to a new multi-month low.
deraktionaer.de/artikel/pharma-biotech/bayer-aktie-faellt-und-faellt-aufwaertstrend-in-gefahr-20412747.html
Bayer exceeds expectations - | the details: Bayer surpasses market expectations.
deraktionaer.de/artikel/pharma-biotech/bayer-toppt-die-erwartungen-die-details-20405988.html
Bayer: Monsanto acquisition costs over 24 billion euros for plaintiffs and lawyers
handelsblatt.com/unternehmen/industrie/bayer-monsanto-kauf-kostet-ueber-24-milliarden-euro-fuer-klaeger-und-anwaelte/100216753.html
Bayer slips deep into the red due to glyphosate lawsuits: The glyphosate lawsuits in the US continue to weigh heavily on Bayer. The company is significantly ...
zdfheute.de/wirtschaft/unternehmen/bayer-milliardenverlust-glyphosat-rechtsstreit-100.html
This is how exposed European Big Pharma is to the U.S.: U.S. pricing has been the bigegts issue of the year for drugmakers heavily exposed to the U.S. market.
cnbc.com/2025/12/19/this-is-how-exposed-european-big-pharma-is-to-the-us.html
This is how exposed European Big Pharma is to the U.S.: U.S. pricing has been the bigegts issue of the year for drugmakers heavily exposed to the U.S. market.
cnbc.com/2025/12/19/this-is-how-exposed-european-big-pharma-is-to-the-us.html
Key FactsEuropean Pharma Faces Pressure from U.S. Market Rules
Dec 19, 2025 · Reading time: ~30 sec.
Summary created with AI assistance · Source: cnbc.com
Summary created with AI assistance · Source: cnbc.com
- The U.S. remains the dominant market for many European pharmaceutical companies, with some deriving up to 85% of sales there.
- President Trump’s Most Favored Nations pricing policy aims to lower drug costs in the U.S., potentially reducing pharma companies’ profit margins.
- Major players including AstraZeneca, Novo Nordisk, Roche, and Novartis are increasing investments and negotiating deals to comply with U.S. pricing demands.
- Concerns exist that these pricing measures and production shifts to the U.S. might limit drug availability in Europe and add operational challenges.
Bayer: Asundexian impresses in study and becomes a beacon of hope: In a new stroke study, Bayer is impressing with a drug that caused the company a significant ...
faz.net/aktuell/wirtschaft/unternehmen/bayer-asundexian-ueberzeugt-in-studie-und-wird-hoffnungstraeger-110790576.html
Bayer Crop Science delivers good business figures: Bayer is profiting from its agricultural business. It increased in sales and earnings ...
topagrar.com/acker/news/bayer-bestatigt-konzernausblick-fur-2025-20019971.html
Cory Booker pitches bill to allow lawsuits against pesticide makers over ‘toxic products’
theguardian.com/us-news/2025/jul/17/cory-booker-pesticide-act
Next